- Home
- MSC vs DMAC Comparison
MSC vs DMAC Comparison
Compare MSC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSC | DMAC |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.4M | 342.7M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MSC | DMAC |
|---|---|---|
| Price | $1.85 | $8.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 11.6K | ★ 235.0K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.80 | $3.58 |
| 52 Week High | $6.63 | $10.42 |
Technical Indicators
Market Signals| Indicator | MSC | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 78.31 |
| Support Level | $1.82 | $8.00 |
| Resistance Level | $3.24 | $9.01 |
| Average True Range (ATR) | 0.13 | 0.49 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 7.91 | 89.10 |
Price Performance
Historical ComparisonAbout MSC Studio City International Holdings Limited
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.